Holen Sie sich die Stockscreener-App
74.81
2.37%
1.73
Handel nachbörslich:
73.90
-0.91
-1.22%
Schlusskurs vom Vortag:
$73.08
Offen:
$73.04
24-Stunden-Volumen:
2.89M
Relative Volume:
0.68
Marktkapitalisierung:
$30.91B
Einnahmen:
$9.51B
Nettoeinkommen (Verlust:
$2.64B
KGV:
12.39
EPS:
6.0361
Netto-Cashflow:
$2.14B
1W Leistung:
+7.35%
1M Leistung:
+2.05%
6M Leistung:
-37.65%
1J Leistung:
-47.83%
1-Tages-Spanne:
$73.00
$74.85
1-Wochen-Bereich:
$69.00
$74.85
52-Wochen-Spanne:
$68.77
$148.30
Zoetis Inc Stock (ZTS) Company Profile
Firmenname
Zoetis Inc
Sektor
Telefon
973-822-7000
Adresse
10 SYLVAN WAY, PARSIPPANY, NJ
Compare ZTS vs TAK, TEVA, HLN, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ZTS
Zoetis Inc
|
74.81 | 30.91B | 9.51B | 2.64B | 2.14B | 6.0361 |
TAK
Takeda Pharmaceutical Co Adr
|
18.73 | 59.83B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
41.10 | 47.93B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.32 | 40.99B | 14.54B | 2.22B | 2.58B | 0.4871 |
UTHR
United Therapeutics Corp
|
549.16 | 23.55B | 3.17B | 1.29B | 1.01B | 27.09 |
Zoetis Inc Stock (ZTS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-08-06 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2026-05-27 | Herabstufung | Argus | Buy → Hold |
| 2026-04-15 | Eingeleitet | Citigroup | Buy |
| 2026-01-22 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2025-12-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-12-09 | Eingeleitet | Barclays | Equal Weight |
| 2025-11-21 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2025-07-17 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-06-18 | Herabstufung | Stifel | Buy → Hold |
| 2024-12-02 | Eingeleitet | Leerink Partners | Outperform |
| 2024-07-25 | Eingeleitet | BTIG Research | Buy |
| 2024-01-12 | Bestätigt | Stifel | Buy |
| 2023-12-19 | Fortgesetzt | Jefferies | Buy |
| 2023-12-07 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2023-09-06 | Eingeleitet | HSBC Securities | Buy |
| 2022-07-12 | Eingeleitet | Piper Sandler | Overweight |
| 2021-11-18 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-07-16 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2021-03-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-03-08 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2020-09-21 | Eingeleitet | Atlantic Equities | Overweight |
| 2020-08-14 | Hochstufung | Edward Jones | Hold → Buy |
| 2020-08-12 | Herabstufung | Gabelli & Co | Buy → Hold |
| 2020-05-27 | Eingeleitet | Jefferies | Buy |
| 2020-01-10 | Eingeleitet | Raymond James | Mkt Perform |
| 2019-09-09 | Eingeleitet | Goldman | Buy |
| 2019-07-01 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-06-11 | Eingeleitet | Barclays | Overweight |
| 2019-05-23 | Eingeleitet | Guggenheim | Buy |
| 2019-05-03 | Herabstufung | Gabelli & Co | Buy → Hold |
| 2019-03-20 | Eingeleitet | SunTrust | Hold |
| 2019-03-04 | Hochstufung | Stifel | Hold → Buy |
| 2019-01-23 | Eingeleitet | UBS | Neutral |
| 2018-10-15 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-08-22 | Herabstufung | Stifel | Buy → Hold |
| 2018-08-03 | Bestätigt | Stifel | Buy |
| 2018-04-19 | Bestätigt | Citigroup | Buy |
| 2018-03-19 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2018-02-16 | Bestätigt | Stifel | Buy |
| 2018-01-04 | Hochstufung | Citigroup | Neutral → Buy |
Alle ansehen
Zoetis Inc Aktie (ZTS) Neueste Nachrichten
Is it the Right Time to Add Phibro Stock to Your Portfolio? - Zacks Investment Research
Zoetis' Simparica Trio Shows Superior Heartworm Protection; ZTS Dividend Remains Attractive - GuruFocus
Zoetis Reports Q2 2026 Results: Full Earnings Call Transcript - Benzinga
Zoetis Inc. stock outperforms competitors on strong trading day - MarketWatch
Zoetis Inc. stock outperforms competitors on strong trading day - MarketWatch
Zoetis (CEUX:ZOED) Change In Prepaid Assets : €0.00 Mil (TTM As of Jun. 2026) - GuruFocus
Vietnam Veterinary Vaccine Import Market and Top 10 Importers Guide 2023-2026 | Import Reliance and Aquaculture Growth Create Market Entry Opportunities - GlobeNewswire Inc.
Zoetis (ZTS) Has a Huge Animal Health Moat. Is It Starting to Crack? - Yahoo Finance
Zoetis (ZTS) Stock Sinks As Market Gains: Here's Why - Zacks Investment Research
Zoetis (ZTS) Stock Sinks As Market Gains: Here's Why - Yahoo Finance
Zoetis Inc. stock underperforms Thursday when compared to competitors - marketwatch.com
US98978VAX1 Bond Profile: Coupon and Redemption - TradingView
Zoetis stock hits 52-week low at $69.48 - Investing.com
Join Class Action to Recover Losses from Zoetis Inc. (ZTS) – Contact Levi & Korsinsky Before July 27, 2026 - ACCESS Newswire
PFE4666688 Bond Profile: Coupon and Redemption - TradingView
Zoetis shares drop 71% since 2021 but remain a buy with strong margins and pipeline potential. - Pluang
Zoetis: Priced For The Worst, Worth Buying (NYSE:ZTS) - Seeking Alpha
Zoetis Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Zoetis Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
PFE4538720 Bond Profile: Coupon and Redemption - TradingView
Zoetis Adds Equine Hematology Capabilities to Vetscan OptiCell and Vetscan Imagyst - myvetcandy.com
Veterinary Diagnostics Market Size to Soar to USD 30.78 Billion by 2035 at a CAGR of 10.1%SNS Insider - GlobeNewswire Inc.
Zoetis Inc. stock outperforms competitors on strong trading day - MarketWatch
Zoetis (ZTS) Registers a Bigger Fall Than the Market: Important Facts to Note - Yahoo Finance
Zoetis Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Zoetis to Host Webcast and Conference Call on Third Quarter 2026 Financial Results - Business Wire
Zoetis Inc. stock outperforms competitors despite losses on the day - MarketWatch
Zoetis (ZTS) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo Finance
Zoetis Stands by Guidance as Pet-Care Weakness and Competition Pressure Sales - Yahoo Finance
Michael Burry Sells FLUT To Pile Into LULU Under $100 — Plus A New Bet On ZTS - TradingView
Why Are Zoetis (NYSE:ZTS) Diagnostics in S&P 500 Focus? - Kalkine Media
Pfizer Stock Or Zoetis: Is The Comeback Worth Paying Up For? - Yahoo Finance
Pfizer Stock Or Zoetis: Is The Comeback Worth Paying Up For? - Trefis
Zoetis Shares Slide Following Earnings RevisionEarnings Deceleration Risk - vinanet.vn
Zoetis Stock (ZTS) Opinions on Michael Burry Portfolio Update - Moomoo
Zoetis Stock (ZTS) Opinions on Michael Burry Portfolio Update - Quiver Quantitative
Zoetis Taps Former GE HealthCare CFO Jay Saccaro as CFO and COO - The Healthcare Technology Report.
Zoetis Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Paws and profits: Zoetis appoints global diagnostics president, NVA names chief medical officer, and more updates - DVM360
Zoetis (ZTS) Shares Drop After Earnings Revision - Yahoo Finance
Veterinary Diagnostic Markets Report Now Available — See Exactly How IDEXX, Zoetis, Antech, Roche, and Thermo Fisher Are Positioned to Win Through 2030 - GlobeNewswire Inc.
Zoetis Inc. (ZTS) Investor Outlook: Unlocking a 26.63% Upside Potential in the Healthcare Sector - DirectorsTalk Interviews
Is Zoetis Stock Underperforming the S&P 500? - Yahoo Finance
Zoetis Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Zoetis to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference - BioSpace
Zoetis to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference - Business Wire
Zoetis (NYSE:ZTS) Offers Value and Quality in One Attractive Package - ChartMill
Zoetis Inc. (ZTS) - DirectorsTalk Interviews
Zoetis Inc. stock outperforms competitors on strong trading day - MarketWatch
Is It Too Late to Buy Zoetis Inc (ZTS) After 3.1% Rally? GF Value Says Undervalued - GuruFocus
Finanzdaten der Zoetis Inc-Aktie (ZTS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Zoetis Inc-Aktie (ZTS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Bisaro Paul | Director |
May 13 '26 |
Buy |
75.88 |
2,000 |
151,750 |
27,862 |
| MCCALLISTER MICHAEL B | Director |
May 11 '26 |
Buy |
77.76 |
3,000 |
233,273 |
24,524 |
| PECK KRISTIN C | Chief Executive Officer |
Feb 17 '26 |
Option Exercise |
41.83 |
20,000 |
836,600 |
121,337 |
| PECK KRISTIN C | Chief Executive Officer |
Feb 17 '26 |
Sale |
127.05 |
20,000 |
2,540,964 |
101,337 |
| Polzer Robert J | Officer |
Feb 17 '26 |
Proposed Sale |
127.34 |
2,346 |
298,742 |
0 |
| PECK KRISTIN C | Officer |
Feb 17 '26 |
Proposed Sale |
127.05 |
20,000 |
2,540,964 |
0 |
| Polzer Robert J | Officer |
Feb 13 '26 |
Proposed Sale |
129.09 |
3,662 |
472,728 |
0 |
3.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):